Protocol: REMAP-CAP: Randomised, Embedded, Multifactorial, Adaptive Platform trial for Community Acquired Pneumonia

EudraCT number: 2015-002340-14

I have read the REMAP-CAP Core Protocol and Appendices listed below. I will provide copies and relevant information to all study staff to ensure they are fully informed on how to conduct the study.

I agree to conduct the study in accordance with the current protocol.

* REMAP-CAP\_Core Protocol\_V3.1, 09-nov-2022
* REMAP-CAP\_Statistical Analysis Appendix\_V3.0, 24-Aug-2019
* REMAP-CAP\_European Region Specific Appendix\_V3.6, 17-Dec-2020
* REMAP-CAP\_Pandemic Appendix to Core\_V2.0, 18-May-2020
* REMAP-CAP\_Antibiotic Domain Specific Appendix\_V3.0, 10-Jul-2019
* REMAP-CAP\_Corticosteroid Domain Specific Appendix\_V5.1, 16-Oct-2023
* REMAP-CAP\_Cysteamine Domain Specific Appendix\_V1.0, 21-Jun-2021
* REMAP-CAP\_Anticoagulation Domain Specific Appendix V3.0, 27-Feb-2021
* REMAP-CAP\_Influenza Antiviral Domain Specific Appendix V2.2, 16-Oct-2023
* REMAP-CAP\_Macrolide Duration Domain Specific Appendix\_V3.0, 10-Jul-2019
* REMAP-CAP\_Immunoglobulin Domain Specific Appendix\_V3.0, 29-Nov-2021

|  |  |
| --- | --- |
| Site code (ABC-XYZ) |  |
| Site Name |  |
| PI Name |  |
| Date (ddMMMyyyy) |  |
| Signature |  |